EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

The role of linker histone H1.2 in tumor progression, resistance, and clinical translation

Jiayang Zhou, Jiajian Shi, Ling Zheng, Kun Huang, Yangkai Li

Epigenomics · 03.10.2026 · 18 (10) · 1277-1293

DOI: 10.1080/17501911.2026.2740944 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Epigenomics, online erschienen am 01.10.2026. Verfasst von Jiayang Zhou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Histones, Neoplasms, Drug Resistance, Neoplasm. Die Arbeit nennt 131 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Hubei Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Linker histone H1 has traditionally been regarded as a structural scaffold that stabilizes higher-order chromatin organization. Recent evidence, however, indicates that H1 variants are dynamic chromatin regulators with variant-specific functions in cancer. Among them, H1.2, encoded by H1-2 (formerly HIST1H1C), has emerged as a context-dependent regulator of chromatin compaction, DNA damage signaling, transcription, stress adaptation, and cell fate. This review summarizes the structural and post-translational features of H1.2 and examines how these properties contribute to tumor progression, invasion, metastasis, and therapeutic resistance. We focus on H1.2-mediated control of the cell cycle, Polycomb-dependent gene silencing, oncogenic transcriptional programs, genotoxic stress tolerance, redox-metabolic adaptation, apoptosis evasion, epithelial-mesenchymal transition-associated drug tolerance, and immune microenvironment remodeling. We also evaluate H1.2 as a tissue-based or circulating biomarker, a post-translational modification-based functional readout, and a guide for biomarker-driven combination therapy. Although direct pharmacological targeting remains preliminary, isoform-selective modulation and interventions targeting H1.2-associated regulatory pathways may expand its future therapeutic potential in precision oncology. Linker histone H1.2 helps organize DNA inside the nucleus. It also helps control which genes are active and how cells respond to damage or other stress. These functions matter in cancer because tumor cells use many of the same systems to grow, spread, and survive treatment.This review describes what is known about H1.2 in cancer. In some solid tumors, higher H1.2 activity has been linked to growth, spread, and treatment resistance. In some blood cancers, loss of H1 proteins can also disturb DNA organization and support cancer. The effect of H1.2 therefore depends on the cancer type and the state of the cell.H1.2 is being studied as a possible marker of tumor behavior and treatment response. No validated blood test can yet measure circulating H1.2 specifically, and most patient evidence comes from retrospective studies. Larger prospective studies and more specific tests are needed before H1.2 can guide routine cancer care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HistonesNeoplasmsDrug Resistance, NeoplasmHumansDisease ProgressionProtein Processing, Post-TranslationalAnimalsChromatin Assembly and Disassembly

Stichwörter der Autor:innen

DNA damage responseLinker histone H1.2biomarkerchromatin remodelingpost-translational modificationprecision oncologytumor progression

Substanzen

Histones

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • School of Pharmacy, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology, Wuhan, China.
  • College of Life Sciences, Wuhan University, Wuhan, China.

Förderung

  • Natural Science Foundation of Hubei Province
  • National Natural Science Foundation of China

Zitieren

APA

Zhou, J., Shi, J., Zheng, L., Huang, K., & Li, Y. (2026). The role of linker histone H1.2 in tumor progression, resistance, and clinical translation. Epigenomics, 1-17. https://doi.org/10.1080/17501911.2026.2740944

Vancouver

Zhou J, Shi J, Zheng L, Huang K, Li Y. The role of linker histone H1.2 in tumor progression, resistance, and clinical translation. Epigenomics. 2026:1-17. doi:10.1080/17501911.2026.2740944

BibTeX
@article{Zhou2026,
  author = {Zhou, Jiayang and Shi, Jiajian and Zheng, Ling and Huang, Kun and Li, Yangkai},
  title = {The role of linker histone H1.2 in tumor progression, resistance, and clinical translation},
  journal = {Epigenomics},
  year = {2026},
  pages = {1--17},
  doi = {10.1080/17501911.2026.2740944}
}
Kostenlos starten →